Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  folic acid
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 30 for your search:
Start Over
Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic
Phase: Phase IV
Type: Prevention
Status: Completed
Age: 20 to 65
Sponsor: NCI, Other
Protocol IDs: AAAC8618, R01CA133595, NCT01050556
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
Phase: Phase IV
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: DERMATUX, NCT01315990
Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: AIO-KRK-0207, ML21768, EudraCT-Nr.: 2008-007974-39, NCT00973609
Phase I/II Study of Lometrexol in Patients with Ovarian Adenocarcinoma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-91173, NCI-V92-0026
Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CAM201, NCT00291785
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-009, NCT00481871
High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed
Phase: Phase II
Type: Prevention
Status: Closed
Age: 21 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000064180, E-8292, NCI-P95-0066, NCT00002650
Phase II Study of Allogeneic and Syngeneic Bone Marrow Transplantation in Patients with High-Risk Myelodysplastic Syndrome (Summary Last Modified 06/93)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 6 months to 65 years
Sponsor:
Protocol IDs: EUC-47491, NCI-V92-0171
Chemoprevention With Folic Acid
Phase: Phase II
Type: Prevention
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: ONCO-021-98S, NCT00018551
Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: HOG GU03-67, NCT00216099
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9732, H3E-MC-S077, NCT00330915
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-008, 2006-002811-29, NCT00364923
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000579360, UAB-F060511015, UAB-IRB0000196, F060511015, NCT00703196
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11652, H3E-CR-S111, NCT00609518
Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-015, NCT00998946
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDX-014, 2008-006425-14, NCT01118624
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-112, NCT01183065
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: HANSOH20090601, NCT01194453
Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: UOSG-AMC-0804, NCT01490437
Phase I Study of Lometrexol/Folic Acid for Solid Tumors and Lymphomas (Summary Last Modified 08/97)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MCV-MCC-9408-2B, NCI-T94-0121O, T94-0121
Phase I Study of Lometrexol/Folic Acid for Advanced Solid Tumors (Summary Last Modified 02/96)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: NCI
Protocol IDs: LAC-USC-0C941, NCI-T94-0142H, T94-0142
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 40 to 72
Sponsor: NCI, Other
Protocol IDs: CDR0000393455, P30CA016056, RUH-PHO-0514-0404, RPCI-EPR-20703, AECM-0401022E, NEMCH-6060, NCT00096330
Phase I Study of the Effects of Dietary Folate Intake on DNA in Colonic Tissue and Peripheral Blood Mononuclear Cell Samples From Patients With Increased Risk for Developing Colorectal Neoplasia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Prevention
Status: Completed
Age: 40 to 72
Sponsor: NCI
Protocol IDs: RUH-PHO-0514-0306, PHO-0514-0306, NCT00611000
Start Over